2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2137

Subchondral Bone Structure and Pain Behaviors in Collagenase Induced Noninflammatory Monoarthritis in Mice
Abstract Number: 1721

Subclinical Atherosclerosis Evolution during 5 Years of Anti-Tnfalpha Treatment in Psoriatic Arthritis Patients: Preliminary Data
Abstract Number: 1000

Subclinical Cytomegalovirus Viremia Is Associated with Increased Nosocomial Infections and Prolonged Hospitalization in Patients with Systemic Autoimmune Diseases
Abstract Number: 1782

Subclinical Myocarditis in Systemic Lupus Erythematosus Patients without Cardiovascular Disease
Abstract Number: 2739

Subclinical Ungueal Distrophy in Patients with Psoriasis without Joint Involvement: Is There Any Role for Nail Ultrasound?
Abstract Number: 948

Subcutaneous Abatacept in Patients with Polyarticular-Course Juvenile Idiopathic Arthritis and Inadequate Response to Biologic or Non-Biologic Disease-Modifying Antirheumatic Drugs: Pharmacokinetics, Efficacy and Safety
Abstract Number: 521

Subcutaneous Adipose Tissue from Rheumatoid Arthritis Patients Is Characterized By an Abundance of Macrophages That Are Associated with Autoantibodies, Systemic Inflammation, and Immunomodulation
Abstract Number: 2559

Subgingival Microbiome Signatures in Patients with Established Rheumatoid Arthritis and Osteoarthritis
Abstract Number: 1481

Success Rate of Blood Pressure Goal Achievement in Patients with Inflammatory Joint Diseases
Abstract Number: 2061

Successful Treatment of Murine Lupus Nephritis with Helminths Related Tuftsin-Phosphorylcholine Compound and Its Effect on the Microbiota
Abstract Number: 2316

Successful Treatment of Statin-Induced Autoimmune Myopathy without Corticosteroids
Abstract Number: 1024

Superior Gains in Bone Mineral Density and Estimated Strength at the Hip for Romosozumab Compared with Teriparatide in Women with Postmenopausal Osteoporosis Transitioning from Bisphosphonate Therapy: Results of a Phase 3, Open-Label Clinical Trial
Abstract Number: 1524

Suppletion Therapy May be Warranted in RA Patients with Co-Existent Subclinical Hypothyroidism
Abstract Number: 1442

Suppression of Acute Arthritis By N-Methyl-3,4-Dichloropropionaniline (N-MeDCPA), a Reversible Orai Calcium Channel Inhibitor
Abstract Number: 1460

Suppression of Cholesterol Levels and Impairment in Cholesterol Efflux By HDL in K/BxN Mice Is Associated with a Specific Cytokine/Chemokine Profile

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].